SITAPRIDE DM 1000

About

This combination medication contains Dapagliflozin, an SGLT2 inhibitor, and Metformin, a biguanide, offering a comprehensive approach to managing type 2 diabetes mellitus. Dapagliflozin reduces blood glucose by inhibiting glucose reabsorption in the kidneys, leading to increased urinary glucose excretion. Metformin acts by decreasing glucose production in the liver, reducing glucose absorption from the gut, and enhancing insulin sensitivity in peripheral tissues. This synergistic action helps achieve better glycemic control in adults with type 2 diabetes when diet and exercise alone are insufficient. Furthermore, dapagliflozin has demonstrated significant benefits in reducing the risk of cardiovascular death, hospitalization for heart failure, and progression of chronic kidney disease in relevant patient populations.

Uses

• Treatment of type 2 diabetes mellitus.
• Improvement of glycemic control in adults.
• Used as an adjunct to diet and exercise.
• When monotherapy with metformin or dapagliflozin is inadequate.

Directions For Use

Take this medication orally, usually once or twice daily with meals, as prescribed by your healthcare provider. Swallow the tablet whole with water.

Benefits

• Effective in lowering blood glucose and HbA1c.
• Dual mechanism of action for robust control.
• Contributes to modest weight loss.
• Reduces risk of heart failure hospitalization.
• Slows progression of chronic kidney disease.
• Improves insulin sensitivity.

Side Effects

• Genital mycotic infections
• Urinary tract infections
• Increased urination
• Nausea
• Diarrhea
• Abdominal discomfort
• Headache
• Dizziness
• Hypotension
• Diabetic ketoacidosis (rare)
• Lactic acidosis (rare, Metformin)
• Vitamin B12 deficiency (Metformin)

Safety Measures

• Alcohol - Avoid excessive alcohol intake due to increased risk of lactic acidosis (metformin) and potential for dehydration or ketoacidosis (dapagliflozin).
• Pregnancy - Not recommended during the second and third trimesters due to potential adverse effects on fetal renal development. Consult your doctor for alternative treatments.
• Breastfeeding - Metformin is present in breast milk; dapagliflozin's presence is unknown. Due to potential risks to the infant, breastfeeding is generally not advised.
• Liver - Metformin is contraindicated in severe hepatic impairment due to increased risk of lactic acidosis. Dapagliflozin does not typically require dose adjustment for mild to moderate impairment.
• Kidney - Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²) due to metformin accumulation. Dapagliflozin's efficacy is reduced with declining renal function; not recommended for initiation below eGFR 25 mL/min/1.73m².
• Lung - No specific contraindications related to lung conditions. However, conditions associated with hypoxia can increase the risk of lactic acidosis with metformin.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.